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Primary signet-ring cell carcinoma of the urinary bladder is a rare tumor. The overall incidence is approximately 0.12-0.6% 
of all urinary bladder malignancies. The majority of the patients present in an advanced stage with a uniformly grim 
prognosis. As signet-ring cell carcinomas are more common in the gastrointestinal tract, a possibility of metastasis needs 
to be considered. Here we report, a 42-year-old patient who presented with hematuria and was diagnosed with a urinary 
bladder tumor. The patient was managed with partial cystectomy and pelvic lymph node dissection. The histopathological 
examination confirmed primary signet-ring cell carcinoma of the urinary bladder. 
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INTRODUCTION
Primary signet-ring cell carcinoma (PSRCC) of 
the urinary bladder is a rare type of adenocarcinoma 
and was first reported in 1955 by Saphir et al.1 The 
overall prevalence remains 0.12-0.6% of all primary 
malignancies of the urinary bladder.2 The majority of 
patients are in their seventh to the eighth decade of 
life with male preponderance. Approximately 25% 
of patients show distant metastasis, and about 50% 
of cases present with locally advanced disease at the 
time of diagnosis.3 PSRCC arises from the urothelium. 
Urothelium undergoes glandular metaplasia secondary 
to chronic irritation and is thought to be a precursor 
lesion of PSRCC. Clinical presentation is similar to other 
primary bladder tumors, which is hematuria. Another 
rare presentation is mucinuria reported in 3-12% of 
the individuals.4 Radiological features are often non-
specific. Therefore, cystoscopic evaluation is extremely 
important. However, in the linitis-plastica variant, no 
mucosal lesion is seen on cystoscopy. Hence early 
diagnosis becomes difficult in these cases.5 Signet-ring 
cell carcinoma is far more common outside the urinary 
bladder and is mostly seen in the gastrointestinal tract. 
Hence the possibility of metastasis should always be 
considered, and a thorough workup is needed to rule 
out primary elsewhere.6,7 Surgical therapy remains the 
mainstay of treatment with or without postoperative 
chemotherapy. The prognosis remains uniformly poor 
in PSRCC. Elevated serum CEA level and diffuse linitis 
plastica like morphology are usually associated with a 
grim prognosis.8 We present a case of primary signet-
ring cell carcinoma located in the urinary bladder’s 
dome in a 42-year-old male presenting with hematuria 
who was managed with partial cystectomy and pelvic 
lymph node dissection. The diagnostic approach, 
differentiating features, prognosis, and survival have 
been discussed.
Primary signet-ring cell carcinoma of the urinary bladder
2-7 Autops Case Rep (São Paulo). 2021;11:e2021264
CASE REPORT
A 42-year-old male presented to the urology 
outpatient clinic with painless and gross hematuria 
with clots of four weeks duration. He was a chronic 
smoker but denied loss of weight or appetite. His 
past medical and family history was non-remarkable. 
On examination, the patient was conscious, alert 
and his vitals were stable. Systemic examination was 
grossly normal. Digital rectal examination showed 
grade 1 prostate, benign, and the lateral pelvic wall 
appeared normal. The abdominal ultrasound reported 
a solitary 3x2 cm papillary growth in the dome of the 
urinary bladder. The rest of the urinary bladder and 
bilateral kidneys were normal. His routine laboratory 
workup was within normal limits. Urine cytology 
revealed abundant atypical cells. The patient was 
counseled and planned for transurethral resection 
of the urinary bladder tumor (TURBT) under regional 
anesthesia. Using a 26-French resectoscope and 
30-degree lens, a complete resection of the tumor 
was done, and a deep muscle biopsy was sent 
separately for assessment. The postoperative course 
was uneventful. The histopathological examination 
showed an invasive urothelial tumor with glandular 
differentiation suggestive of adenocarcinoma. The 
detrusor muscle invasion was present. At 3 weeks of 
follow up, a staging workup was done. The abdominal 
contrast-enhanced computed tomography (CECT) 
revealed mild thickening in the dome of the urinary 
bladder and a perivesical fat stranding with an enlarged 
right obturator lymph node measuring 16x7 mm. The 
positron emission tomography (PET) scan revealed 
fluorodeoxyglucose (FDG) avid uptake in the dome 
of the urinary bladder and right obturator node with 
no other focus elsewhere (standardized uptake values 
max 6.1). The chest x-ray, liver function test, upper 
gastrointestinal endoscopy, and colonoscopy were 
unremarkable. Serum prostate-specific antigen (PSA) 
was of 2.1 ng/ml (reference range [RR]; 0-4 ng/ml), CA 
19-9 of 10 IU/ml (RR: 0-37 U/ml) and carcinoembryonic 
antigen (CEA) of 1.9 ng/ml (RR: < 2.5 ng/ml). In view of 
the localized disease to the dome of the urinary bladder 
and histopathology reporting as adenocarcinoma, 
partial cystectomy with bilateral pelvic lymph node 
dissection was planned. A midline infra umbilical 
laparotomy was undertaken. The urinary bladder’s 
dome was excised with a 2 cm margin all around 
the scar of previous surgery, along with a standard 
bilateral pelvic lymph node resection was performed. 
The post-operative was uneventful. The surgical 
specimen consisted of an unoriented partial cystectomy 
measuring 40x26x20 mm. A solitary exophytic growth 
was noted in the mucosa measuring 20x20x8mm. 
Multiple sections were taken, including the soft tissue 
resection limits. Sections study showed tumor cells’ 
sheets with an occasional glandular configuration 
in a background of abundant extracellular mucin 
(Figure 1A). The tumor cells were predominantly 
(>90%) signet-ring-shaped with intracellular mucin 
accumulation (Figure 1B). The tumor cells infiltrated up 
to the inner half of the superficial muscularis propria 
(Figure 1C). No extension into the perivesical tissue 
was noted. Lymphatic emboli were present, but no 
perineural invasion. The tumor was 7 mm away from 
the surgical soft tissue resection planes. Only 2 of the 
5 lymph nodes of the right pelvic group and none of 
the 6 lymph nodes of the left pelvic group showed 
metastasis (Figure 1D).
The final histopathological impression was 
T2aN2M0 Signet-ring cell carcinoma. A panel 
of immunostainings (Table 1) was carried out to 
differentiate between a primary and metastatic tumor. 
Diffuse positivity for CEA and CK20 were detected 
(Figure 2A, 2B). Nuclear positivity for CDX2 was 
detected, and E- cadherin was retained by the tumor 
cells (Figure 2C, 2D).
No positivity was observed for PSA, GATA3 
(Figure 3A), and AMACR. Faint and patchy positivity 
for CK7 was noted. Immunostain for β-catenin 
(Figure 3B) showed no nuclear staining, and CD138 
immunostaining failed to stain any of the tumor cells. 
Based on these immune profiles, it confirmed primary 
signet-ring cell carcinoma of the urinary bladder.
The per-urethral catheter was removed after 
3 weeks. The patient was referred to the Medical 
oncology unit in view of locally advanced disease, and 
he received 4 cycles of double-dense methotrexate, 
vinblastine, doxorubicin, and cisplatin regimen. The 
Table 1. Results of IHC
Positive 
reaction




reaction GATA3 PSA CD138 β-catenin
M= membrane; n= nuclear.
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patient tolerated the chemotherapy regimen well. At 
6 months follow-up, a check cystoscopy was normal, 
and the CECT of the chest and abdomen showed no 
evidence of recurrence. The patient was planned for 
cystoscopy surveillance at 3 monthly intervals for the 
next 2 years.
DISCUSSION
PSRCC was first described in 1955. About 300 cases 
have been published, so far, in the English literature.2 
The prognosis of PSRCC remains uniformly poor as it 
presents in an advanced stage and is commonly resistant 
to chemo and radiotherapy.1,2 This tumor commonly 
affects elderly male patients mostly in their sixth decades 
and characterizes a rapidly aggravating clinical course.6 
Approximately 65% of the patients present with 
hematuria.7 On imaging, it may appear as diffuse wall 
thickening of the urinary bladder. At cystoscopy, and 
two-third of the cases present with exophytic growth. 
However, even urothelial carcinoma may present with 
diffuse fibrous thickening of the wall without any 
obvious mucosal lesion, which challenges the cystoscopic 
detection.8-10 Reactive proliferation is sometimes seen 
in the native urothelium (von-Brunn nest), mostly 
secondary to inflammation or chronic irritation, which 
is also responsible for cystic changes and subsequent 
glandular or intestinal metaplasia of the urothelium. This 
metaplastic mucosa acts as a precursor lesion of invasive 
adenocarcinomas, including signet ring cell carcinomas.11 
Three, theories have been proposed in the published 
literature regarding the pathogenesis of PSRCC of the 
urinary bladder, namely (i) the PSRCC arises from the 
metaplastic epithelium of the cystitis cystica, and (ii) the 
neoplastic transformation of the totipotent urothelial 
cells without any metaplastic changes. Lastly, the urinary 
bladder PSRCC can also arise from the isolated signet-ring 
cell from the urothelium.7,11,12
Figure 1. Photomicrography of tumor. A – Signet-ring cells are diffusely scattered with extracellular mucinous lakes 
(H&E, 4X); B – Signet-ring cells with intracellular mucin and nuclei pushed to the periphery (H&E, 40X); C – Tumor 
cells are infiltrating muscularis propria (H&E, 20X); D – Tumor cells have metastasized to the lymph node (H&E, 20X).
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The cytomorphological detail of signet ring 
cell carcinoma has been described by Guan et al.13 
According to them, the cytospin smears were 
hypercellular with mixed inflammatory cells in 
the background. Scattered signet ring cells were 
described as large cells with eccentrically placed nuclei, 
prominent nucleoli, and discrete mucin vacuoles in the 
abundant cytoplasm. In primary urothelial carcinoma 
Figure 2. Photomicrography of bladder tumor. A – Tumor cells are diffusely positive for CEA (10X); and B – CK20 
(10X); C – Nuclear positivity for CDX2 is noted (20X); D – Membranous positivity for E-cadherin is seen (20X).
Figure 3. Photomicrography of the bladder tumor. A – Tumor cells are negative for GATA3; internal control positive 
(10X); B – β- catenin immunostaining shows the absence of nuclear positivity (20X).
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with signet ring cell features, the signet ring cells 
were admixed with coexisting malignant glandular 
epithelial cells.13 The histomorphological features 
of urinary bladder PSRCC is quite characteristic. 
Loosely cohesive signet-ring cells are scattered 
containing intracellular mucin abutting nuclei to the 
periphery.2 While diagnosing urinary bladder PSRCC, 
it is mandatory to rule out metastatic tumors from the 
gastrointestinal tract. The immunostainings for CK7, 
CK20, CEA, EMA, and CDX2 cannot differentiate the 
urinary bladder PSRCC from the primary signet-ring 
cell carcinoma of the gastrointestinal tract as the 
immunohistochemical profile often overlaps. However, 
the absence of nuclear positivity for β-catenin with no 
endoscopically detectable lesion in the gastrointestinal 
tract favors urinary bladder origin.14 In the present 
case, the tumor cells were positive for CEA, CK20, 
and CDX2. β-catenin positivity was restricted to the 
cell membrane, supporting the primary bladder origin. 
It is essential to mention that gathering information 
on immunohistochemistry, clinical features, imaging, 
and other invasive diagnostic modalities plays a vital 
role in reaching a definite diagnosis.2 Hence, upper 
and lower gastrointestinal endoscopy and chest X-ray 
have been done in this case to rule out the possibility of 
other origin sites. Another crucial differential diagnosis 
of PSRCC is the plasmacytoid variant of urothelial 
carcinoma. The plasmacytoid variant of urothelial 
carcinoma is a rare and aggressive variant showing 
plasmacytoid differentiation with signet-ring cells, and 
the cells are positive for CK7, GATA3, CD138, and 
CK20. Loss of E-cadherin is also an important additional 
finding present in the plasmacytoid variant of urothelial 
carcinoma, which was not seen in the index case.14,15 
The possibility of primary urachal adenocarcinoma was 
also thought as the location of the tumor was in the 
dome of the bladder. Almost all urachal neoplasms 
arise from the dome. Amin et al.16 conducted one 
of the larger studies on the urachal tumors. They 
included a total of 55 cases, and out of them, 24 
cases (44%) were invasive non-cystic adenocarcinoma. 
Out of these 24 cases of adenocarcinoma, five cases 
show signet ring cells in isolated small clusters and 
single scattered. Only one case showed diffusely 
infiltrative signet ring cells with 80% cells of signet 
ring cell morphology.16 There are very few published 
case reports of urachal signet ring cell carcinoma. 
Therefore, primary urachal adenocarcinoma with 
isolated signet-ring cell differentiation is very rare and 
was not considered in this case.17,18
As there is no consensus guideline for the 
management of PSRCC, input from the diagnostic 
and related clinical subspecialties are required in 
a multidisciplinary setting. PSRCCs are uniformly 
insensitive to radiotherapy and standard chemotherapy. 
Therefore, surgery remains the mainstay of treatment 
in 70% of the cases.3,19 Theoretically, surgeons can 
avail of transurethral resection to radical cystectomy 
with urinary diversion. However, partial cystectomy is 
generally preferred over radical cystectomy, especially 
in small, well-demarcated, localized tumors located 
in the urinary bladder’s dome.2,20 When a cisplatin-
based combined chemotherapy regimen follows 
surgical therapy, it improves the progression-free and 
overall survival.21 The index case underwent partial 
cystectomy with standard pelvic lymph node dissection. 
In follow up, the patient received 3 cycles of adjuvant 
chemotherapy and is currently disease-free on follow 
up.
CONCLUSION
Primary signet-ring cell carcinomas of the urinary 
bladder are uncommon. One should rule out focus at 
other primary landing sites. Staging workup is essential 
in all cases to rule out metastasis. Histopathological 
examination and immunostaining is key to diagnosis. 
Though highly aggressive, partial cystectomy is a 
feasible option in some cases. Follow up is life-long 
to look for recurrence of the disease.
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